STAT
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Vizitează neapărat site-ul podcastului și susține-i creatorul: soundcloud.com
Unde asculți?
Podcasturi în aplicație Replaio Radio În curândPodcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor
Episoade
Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study 15.08.2019 29:38
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work?
Episode 74: Novartis and the no good, very bad week 08.08.2019 19:33
Why did Novartis (NVS) keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?
Episode 73: Canadian pills, corporate jets, & racists with spit kits 01.08.2019 23:51
Will Canada run out of drugs? Should you ever read your partner's diary? And what does Pepe the Frog know about genomics?
Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health 25.07.2019 26:33
What makes an epidemic newsworthy? Can biotech succession succeed? And what's so novel about digital health?
Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety 18.07.2019 25:37
Can apps treat anxiety? Is Gilead Sciences back on track? And are we all just brains in a vat?
Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech 11.07.2019 29:52
Is drug pricing too complex for the Trump administration? Would you recognize Tom Hanks at a party? And what does it mean when famous executives quit?
Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing 27.06.2019 25:31
Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?
Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life 20.06.2019 26:49
Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all?
Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world 13.06.2019 25:03
Is biohacking a crime? Who came up with the latest CRISPR trick? And did Rage Against the Machine sell out?
Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party 06.06.2019 26:52
Who won ASCO? Is pharma sandbagging its blockbusters? And what do gladiators have to do with biotech?
Episode 65: A special episode from the halls of the ASCO meeting 04.06.2019 29:25
What can be done to improve HPV vaccination rates in the U.S.? How does the genetic signature of a tumor lead to an effective cancer drug? What’s it like being a doctor and a cancer patient?
Episode 64: Feuding professors, failing businesses, and journalism 101 30.05.2019 23:59
Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?
Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer 23.05.2019 31:33
What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?
Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials 16.05.2019 23:24
Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?
Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA 09.05.2019 25:03
Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?
Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms 02.05.2019 22:20
Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?
Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup 25.04.2019 22:17
Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?
Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print 18.04.2019 21:34
Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst 11.04.2019 25:21
How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?
Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound 04.04.2019 28:51
What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?
Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges 28.03.2019 26:32
Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?
Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores 21.03.2019 31:04
Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?
Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen 14.03.2019 31:45
Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?
Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation 07.03.2019 28:28
Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?
Episode 51: CEOs at the Senate, merger mania, and sleuthing startups 28.02.2019 26:26
Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?
Podcasturi asemănătoare
Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice